Literature DB >> 15295365

Sexual activity predicts continued pessary use.

Cynthia Brincat1, Kimberly Kenton, Mary Pat Fitzgerald, Linda Brubaker.   

Abstract

OBJECTIVE: The purpose of this study was to determine which clinical variables predict continued pessary use. STUDY
DESIGN: After IRB approval, charts of consecutive women at Loyola Women's Pelvic Medicine Center who bought a pessary from August 2000 to December 2002 were reviewed. Demographic information, length of pessary use, and reason for pessary discontinuation were recorded. Current pessary "users" were compared with "nonusers" (women who stopped wearing the pessary during the study period).
RESULTS: Of the 136 study women, 82 (60%) were "users," and 54 (40%) were "nonusers." Women who were sexually active were more likely to continue pessary use (beta=2.204, P=.021). This was true regardless of indication for pessary placement. Women with prolapse were more likely than women with incontinence to continue with long-term pessary use (beta=2.031, P=.049). No other demographic characteristics predicted continued pessary use.
CONCLUSION: Long-term pessary use is acceptable to sexually active women. Women being treated for pelvic organ prolapse are more likely to continue pessary use than women being treated for urinary incontinence. Additionally, the majority of women (60%) who accept a pessary for prolapse or urinary incontinence continue this treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15295365     DOI: 10.1016/j.ajog.2004.03.083

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  Pessary use in pelvic organ prolapse and urinary incontinence.

Authors:  Keisha A Jones; Oz Harmanli
Journal:  Rev Obstet Gynecol       Date:  2010

2.  Sexual function before and after non-surgical treatment for stress urinary incontinence.

Authors:  Victoria L Handa; Emily Whitcomb; Alison C Weidner; Ingrid Nygaard; Linda Brubaker; Catherine S Bradley; Marie Fidela R Paraiso; Joseph Schaffer; Halina M Zyczynski; Min Zhang; Holly E Richter
Journal:  Female Pelvic Med Reconstr Surg       Date:  2011       Impact factor: 2.091

3.  Successful use of ring pessary with support for advanced pelvic organ prolapse.

Authors:  Jing Ding; Chun Chen; Xiao-Chen Song; Lei Zhang; Mou Deng; Lan Zhu
Journal:  Int Urogynecol J       Date:  2015-05-16       Impact factor: 2.894

Review 4.  Review of current status of female sexual dysfunction evaluation in urogynecology.

Authors:  Ranee Thakar
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-05

5.  Pelvic floor symptom changes in pessary users.

Authors:  Yuko M Komesu; Rebecca G Rogers; Martha A Rode; Ellen C Craig; Katey A Gallegos; Angela R Montoya; Carrie D Swartz
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

6.  Factors influencing long-term pessary use.

Authors:  Sarah Friedman; Katherine S Sandhu; Cuiling Wang; Magdy S Mikhail; Erika Banks
Journal:  Int Urogynecol J       Date:  2010-01-09       Impact factor: 2.894

7.  Sexual Function and Pessary Management among Women Using a Pessary for Pelvic Floor Disorders.

Authors:  Kate V Meriwether; Yuko M Komesu; Ellen Craig; Clifford Qualls; Herbert Davis; Rebecca G Rogers
Journal:  J Sex Med       Date:  2015-12-03       Impact factor: 3.802

8.  Defecatory dysfunction and other clinical variables are predictors of pessary discontinuation.

Authors:  Erin G Dengler; Louisa A Mounsey; Francesca Gines; Manahil Agha; Terri Long; Elizabeth J Geller
Journal:  Int Urogynecol J       Date:  2018-10-20       Impact factor: 2.894

9.  Conservative versus surgical management of prolapse: what dictates patient choice?

Authors:  Dharmesh S Kapoor; Ranee Thakar; Abdul H Sultan; Reeba Oliver
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-06-19

Review 10.  Pessary treatment for pelvic organ prolapse and health-related quality of life: a review.

Authors:  Babet H C Lamers; Bart M W Broekman; Alfredo L Milani
Journal:  Int Urogynecol J       Date:  2011-04-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.